Bluebird Bio | BLUE - Beneficio Operativo



Beneficio Operativo Cambio Fecha
Agios Pharmaceuticals USD -121.58M 4.71M 2025-12
Alnylam Pharmaceuticals USD 29.4M 59.36M 2025-12
Amgen USD 3.96B 464M 2025-12
Arrowhead Research USD 40.81M 3.3M 2025-12
Biogen USD 659.6M 192.2M 2025-09
BioMarin Pharmaceutical USD 198.39M 230.08M 2025-12
Gilead Sciences USD 2.96B 551M 2025-12
Incyte USD 383.88M 47.43M 2025-12
Ionis Pharmaceuticals USD -215M 54.82M 2025-12
Moderna USD -857M 597M 2025-12
Nektar Therapeutics USD -19.09M 15.26M 2025-12
Novartis USD 4.06B 437M 2025-12
Pfizer USD 4.65B 3.99B 2025-12
PTC Therapeutics USD -81.62M 85.11M 2025-12
Regeneron Pharmaceuticals USD 898.6M 211.3M 2025-12
Sangamo BioSciences USD -33.51M 12.77M 2024-06
Sarepta Therapeutics USD -410.08M 347.2M 2025-12
Tectonic Therapeutic USD -21.52M 374K 2025-12
Ultragenyx Pharmaceutical USD -114M 56.89M 2025-12
Vertex Pharmaceuticals USD 1.26B 24.5M 2025-12